Skip to main content
      Understanding Comorbidities in RMD

      People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of

      Dr. John Cush RheumNow

      2 months ago
      Understanding Comorbidities in RMD People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures. EIULAR 2026 showcased new data and ideas around various comorbidities and https://t.co/twr0EiMp9f
      All content is independently chosen and produced by the RheumNow faculty. RheumNow’s expanded coverage of the #EULAR20

      Dr. John Cush RheumNow

      2 months ago
      All content is independently chosen and produced by the RheumNow faculty. RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB.
      Day 1 Report from EULAR 2026

      The first day of EULAR 2026 in London featured the opening ceremonies, a plenary session,

      Dr. John Cush RheumNow

      2 months ago
      Day 1 Report from EULAR 2026 The first day of EULAR 2026 in London featured the opening ceremonies, a plenary session, posters nd the first round of major oral presentations to an audience of nearly 15,000 attendees. Here are a few of my favorites from the first day. https://t.co/qCnoiGedat
      #EULAR2026 Want to catch up with the latest breakthrough in research on the last day of the conference? Please find our

      Md Yuzaiful Md Yusof Yuz6Yusof

      2 months ago
      #EULAR2026 Want to catch up with the latest breakthrough in research on the last day of the conference? Please find our Day 4 Daily Recap led by @RheumNow and joined by my colleagues @synovialjoints @DrMiniDey 😃 https://t.co/fONe6g4ne1 https://t.co/kOqzF8t64w
      RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow a

      Dr. John Cush RheumNow

      2 months ago
      RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.
      Remember
      Babies of pts on chronic #immunosuppression with #SARDs

      ❎delay #vaccinations til 6/12
      For safety & to m

      Janet Pope Janetbirdope

      2 months ago
      Remember Babies of pts on chronic #immunosuppression with #SARDs ❎delay #vaccinations til 6/12 For safety & to mount sufficient response #rotovirus #vaccine is Ok before 6 months or vaccine is ineffective Pts w #SARDs need #COVID shots @RheumNow #EULAR2026 #vaccine #recom https://t.co/WEzNajWlxY
      What’s new with the 2026 update of reco for vax in AIIRD?
      Vaccinate as soon as possible
      Non-live vaccines are safe
      Ho

      sheila RHEUMarampa

      2 months ago
      What’s new with the 2026 update of reco for vax in AIIRD? Vaccinate as soon as possible Non-live vaccines are safe Hold MTX for upto 2wks to inc vax yield Strong reco for RZV Catch-up vax for HPV in SLE Rotavirus vax for newborns exposed in utero to TNFi @RheumNow #EULAR2026 https://t.co/RZbyvAcYRI
      #EULAR2026 #SARD #vaccination #recommendations
      I think 🤔
      ✅proactive➡️take responsibility
      ✅close gap
      ✅most

      Janet Pope Janetbirdope

      2 months ago
      #EULAR2026 #SARD #vaccination #recommendations I think 🤔 ✅proactive➡️take responsibility ✅close gap ✅mostly practical But How long will #shingrix work if #vaccine In age<50yrs When if ever To revaccinate? @RheumNow @eular_org @ACRheum https://t.co/najJwzdecL
      Dr. Cavagna presents the 2025 EULAR/ACR Classification Criteria for Anti-Synthetase Syndrome
      He emphasizes the inportanc

      sheila RHEUMarampa

      2 months ago
      Dr. Cavagna presents the 2025 EULAR/ACR Classification Criteria for Anti-Synthetase Syndrome He emphasizes the inportance of ruling out anti-MDA5 Ab & anti-PM/Scl Ab DM since these conditions share overlapping features w/ ASyS. @RheumNow #EULAR2026 https://t.co/AtGRlp5qyW
      B-cell targeting has moved to the centre of IgG4-related disease treatment, with inebilizumab, a CD19 depleter, as the recent benchmark. At EULAR 2026, INDIGO tested whether the disease can be controlled by switching B cells off rather than depleting them.
      ×